As the prevalence of type 2 diabetes continues to rise globally, the search for effective treatment options intensifies. Among the forefront of advancements are GLP-1 receptor agonists, a class of drugs that improve blood sugar control and have additional benefits for patients with diabetes. Semaglutide and dulaglutide represent two widely recognized options within this category,